Eli Lilly Presents New Exploratory Data From The TOGETHER-PSO Phase 3B Clinical Trial Taltz And Zepbound Compared With Taltz Alone In Adults With Moderate-To-Severe Plaque Psoriasis And Obesity Or Overweight; Data Showed Broader Biomarker Changes With Taltz And Zepbound Vs Taltz Alone
The prespecified analysis, presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, provides new insights suggesting an immunometabolic relationship between psoriasis and obesity. These data showed that
Eli Lilly tested two medicines together on skin and weight problems. The combination showed stronger results than one medicine alone, which hints at how the body works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.